hsa-mir-3614: Hsa-mir-3614 is a microRNA that has been identified in various studies as having a role in cancer. Wu et al. established a risk assessment model that included hsa-mir-3614 as one of the 11 miRNAs used for risk assessment in endometrial cancer [PMC9911505]. Another study found that hsa-mir-3614 is low-expressed in endometrial cancer tissues [PMC9318842]. However, hsa-mir-3614 has been shown to directly target upstream genes to promote cancer cell proliferation and invasion, and its role has been confirmed in renal clear cell carcinoma and non-small-cell carcinoma [PMC9318842]. In terms of prognosis, highly expressed miRNAs such as hsa-mir-138-2, hsa-mir-548f-1, hsa-mir-934, hsa-mir-940, and hsa-mir-4758 are associated with poor prognosis and lower survival rate in endometrial cancer, while low-expressed miRNAs such as hsa-mir-146a, hsa-mir3170, hsa-miR3614 are also associated with poor prognosis [PMC9318842]. In terms of expression levels in endometrial cancer tissues compared to normal tissues, the expression of hsa-miR3614 is highly expressed in tumor tissues [PMC8806668]. The risk score for individuals can be calculated using the expression levels of various miRNAs including the expression level of hsa-miR3614 [PMC8806668]. Overall, studies have shown that the expression level and role of HSA-MIR3614 can have implications for risk assessment and prognosis in endometrial cancer.